Fertility drugs used in IVF do NOT increase the risk of women developing breast cancer, study finds

There was no significant increase in the risk of breast cancer among women treated with any ovarian stimulation drug for infertility, say King's College London scientists.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

J Clin Med. 2021 Sep 18;10(18):4235. doi: 10.3390/jcm10184235.ABSTRACT(1) Background: although most patients with epithelial ovarian cancer (EOC) undergo radical surgery, patients with early-stage disease, borderline ovarian tumor (BOT) or a non-epithelial tumor could be offered fertility-sparing surgery (FSS) depending on histologic subtypes and prognostic factors. (2) Methods: we conducted a systematic review to assess the safety and fertility outcomes of FSS in the treatment of ovarian cancer. We queried the MEDLINE, PubMed, Cochrane Library, and Cochrane ("Cochrane Reviews") databases for articles published i...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
J Clin Med. 2021 Sep 16;10(18):4192. doi: 10.3390/jcm10184192.ABSTRACTA significant number of women receive a cancer diagnosis before their age of natural menopause. Among these patients, the most frequent neoplasms are breast cancer, gynecological, and hematological malignancies. Premature ovarian insufficiency and infertility are among the most feared short- to long-term consequences of anticancer treatments in premenopausal patients. Both patient- and treatment-related characteristics are key factors in influencing the risk of gonadotoxicity with the use of chemotherapy. The cryopreservation of oocytes/embryos is a stan...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
J Clin Med. 2021 Sep 18;10(18):4235. doi: 10.3390/jcm10184235.ABSTRACT(1) Background: although most patients with epithelial ovarian cancer (EOC) undergo radical surgery, patients with early-stage disease, borderline ovarian tumor (BOT) or a non-epithelial tumor could be offered fertility-sparing surgery (FSS) depending on histologic subtypes and prognostic factors. (2) Methods: we conducted a systematic review to assess the safety and fertility outcomes of FSS in the treatment of ovarian cancer. We queried the MEDLINE, PubMed, Cochrane Library, and Cochrane ("Cochrane Reviews") databases for articles published i...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
J Clin Med. 2021 Sep 16;10(18):4192. doi: 10.3390/jcm10184192.ABSTRACTA significant number of women receive a cancer diagnosis before their age of natural menopause. Among these patients, the most frequent neoplasms are breast cancer, gynecological, and hematological malignancies. Premature ovarian insufficiency and infertility are among the most feared short- to long-term consequences of anticancer treatments in premenopausal patients. Both patient- and treatment-related characteristics are key factors in influencing the risk of gonadotoxicity with the use of chemotherapy. The cryopreservation of oocytes/embryos is a stan...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractStudy questionDo different types of cancer affect the success of oocyte maturation in vitro compared to infertile women included in the in vitro fertilization (IVF) program?Summary answerCancer does not adversely affect oocyte maturation in vitro, with the exception of breast cancer, compared to infertile women in the in vitro fertilization program.What is known alreadyVitrification and storage of oocytes in liquid nitrogen is one of the real options for maintaining reproductive function in cancer patients. Despite careful hormonal stimulation of the ovaries, however, the proportion of oocytes is immature and lost ...
Source: Human Reproduction - Category: Reproduction Medicine Source Type: research
THURSDAY, July 1, 2021 -- Women treated with ovarian stimulation drugs for infertility do not have a significantly increased risk of breast cancer, according to a systematic review and meta-analysis published in the July issue of Fertility and...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
J Clin Endocrinol Metab. 2021 Jun 22:dgab461. doi: 10.1210/clinem/dgab461. Online ahead of print.ABSTRACTCONTEXT: In a previous study we reported that anti-Müllerian hormone (AMH), a marker of ovarian reserve, is positively associated with breast cancer risk, consistent with other studies.OBJECTIVE: Assess whether risk factors for breast cancer are correlates of AMH concentration.DESIGN: Cross-sectional.PARTICIPANTS: 3831 healthy premenopausal women (aged 21-57, 87% aged 35-49).SETTING: Ten cohort studies, general population.RESULTS: Adjusting for age and cohort, we observed positive associations of AMH with age at menarche (p
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Source Type: research
J Clin Endocrinol Metab. 2021 Jun 22:dgab461. doi: 10.1210/clinem/dgab461. Online ahead of print.ABSTRACTCONTEXT: In a previous study we reported that anti-Müllerian hormone (AMH), a marker of ovarian reserve, is positively associated with breast cancer risk, consistent with other studies.OBJECTIVE: Assess whether risk factors for breast cancer are correlates of AMH concentration.DESIGN: Cross-sectional.PARTICIPANTS: 3831 healthy premenopausal women (aged 21-57, 87% aged 35-49).SETTING: Ten cohort studies, general population.RESULTS: Adjusting for age and cohort, we observed positive associations of AMH with age at menarche (p
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: By facilitating referral and seeking funds and special discounts for underserved patients, supportive care programs for young women with breast cancer can play a crucial role on enhancing access to oncofertility services that would otherwise be prohibitive because of their high costs, particularly in resource-constrained settings. For these efforts to be successful and widely applied in the long term, sustained and extended governmental coverage of FP options for this young group is warranted.PMID:34153944 | DOI:10.6004/jnccn.2020.7692
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Authors: Source Type: research
To evaluate the evidence addressing the association between the use of ovarian stimulation drugs and the risk of breast cancer.
Source: Fertility and Sterility - Category: Reproduction Medicine Authors: Tags: Original article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Infertility | Ovarian Cancer | Ovaries | Reproduction Medicine | Study | Women